XML 39 R17.htm IDEA: XBRL DOCUMENT
v3.25.4

Other Balance Sheet Components | 12 Months Ended
--- | ---
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Other Balance Sheet Components | 9. Other Balance Sheet Components Accounts Receivable, Net Accounts receivable, net, as of December 31, 2025 and 2024 consisted of the following (in millions):
|  | December 31,
|  | 2025 |  | 2024
Accounts receivable |  | $ | 368 |  |  | $ | 698 |
Less: Wholesalers chargebacks, discounts and fees |  | (181) |  |  | (340) |
Less: Allowance for doubtful accounts |  | (3) |  |  | — |
Accounts receivable, net |  | $ | 184 |  |  | $ | 358 |
Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets, as of December 31, 2025 and 2024 consisted of the following (in millions):
|  | December 31,
|  | 2025 |  | 2024
Prepaid services |  | $ | 169 |  |  | $ | 173 |
Down payments and prepayments related to manufacturing and materials |  | 61 |  |  | 106 |
Interest receivable |  | 42 |  |  | 59 |
Value added tax receivable |  | 37 |  |  | 45 |
Prepaid income tax |  | 33 |  |  | 28 |
Collaboration receivable |  | 13 |  |  | 58 |
Income tax receivable |  | 8 |  |  | 72 |
Other current assets |  | 45 |  |  | 58 |
Prepaid expenses and other current assets |  | $ | 408 |  |  | $ | 599 |
Other Non-Current Assets Other non-current assets, as of December 31, 2025 and 2024 consisted of the following (in millions):
|  | December 31,
|  | 2025 |  | 2024
Income tax receivable, non-current |  | $ | 161 |  |  | $ | 97 |
Inventory, non-current(1) |  | 114 |  |  | 150 |
Down payments and prepayments, non-current |  | 100 |  |  | 139 |
Deferred tax assets |  | 81 |  |  | 81 |
Goodwill |  | 52 |  |  | 52 |
Finite-lived intangible asset |  | 45 |  |  | 40 |
Equity investments |  | 6 |  |  | 14 |
Other |  | 46 |  |  | 21 |
Other non-current assets |  | $ | 605 |  |  | $ | 594 |
_______ (1)Consisted of raw materials with an anticipated consumption beyond one year. Accrued Liabilities Accrued liabilities, as of December 31, 2025 and 2024 consisted of the following (in millions):
|  | December 31,
|  | 2025 |  | 2024
Provisions related to product sales (Note 3) |  | $ | 509 |  |  | $ | 370 |
Compensation-related |  | 420 |  |  | 312 |
Manufacturing |  | 140 |  |  | 109 |
Development operations |  | 106 |  |  | 120 |
Other external goods and services |  | 57 |  |  | 131 |
Property, plant and equipment |  | 45 |  |  | 99 |
Royalties |  | 31 |  |  | 46 |
Raw materials |  | 30 |  |  | 41 |
Commercial |  | 23 |  |  | 45 |
Clinical trials |  | 20 |  |  | 94 |
Loss on future firm purchase commitments(1) |  | 5 |  |  | 60 |
Accrued liabilities |  | $ | 1,386 |  |  | $ | 1,427 |
______ (1)Related to losses that are expected to arise from firm, non-cancellable, commitments for future raw material purchases (Note 7). Other Current Liabilities Other current liabilities, as of December 31, 2025 and 2024 consisted of the following (in millions):
|  | December 31,
|  | 2025 |  | 2024
Estimated reimbursements to wholesalers and distributors |  | $ | 84 |  |  | $ | 103 |
Research and development funding liability (Note 5) |  | 43 |  |  | 58 |
Lease liabilities - financing (Note 10) |  | 25 |  |  | 23 |
Lease liabilities - operating (Note 10) |  | 17 |  |  | 14 |
Other |  | 16 |  |  | 23 |
Other current liabilities |  | $ | 185 |  |  | $ | 221 |
Other Non-Current Liabilities Other non-current liabilities, as of December 31, 2025 and 2024 consisted of the following (in millions):
|  | December 31,
|  | 2025 |  | 2024
Tax liabilities |  | $ | 249 |  |  | $ | 231 |
Other |  | 36 |  |  | 36 |
Other non-current liabilities |  | $ | 285 |  |  | $ | 267 |
Deferred Revenue The following table summarizes the activities in deferred revenue during the year ended December 31, 2025 (in millions):
|  | December 31, 2024 |  | Additions |  | Deductions |  | December 31, 2025
Net product sales |  | $ | 188 |  |  | $ | 108 |  |  | $ | (189) |  |  | $ | 107 |
Other revenue |  | 23 |  |  | 212 |  |  | (90) |  |  | 145 |
Total deferred revenue |  | $ | 211 |  |  | $ | 320 |  |  | $ | (279) |  |  | $ | 252 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration